胰淀素
肾上腺髓质素
降钙素受体
降钙素
降钙素基因相关肽
受体
化学
内分泌学
药理学
内科学
生物
细胞生物学
生物化学
医学
神经肽
小岛
胰岛素
出处
期刊:Pharmacological Reviews
[American Society for Pharmacology and Experimental Therapeutics]
日期:2002-06-01
卷期号:54 (2): 233-246
被引量:792
摘要
The calcitonin family of peptides comprises calcitonin, amylin, two calcitonin gene-related peptides (CGRPs), and adrenomedullin. The first calcitonin receptor was cloned in 1991. Its pharmacology is complicated by the existence of several splice variants. The receptors for the other members the family are made up of subunits. The calcitonin-like receptor (CL receptor) requires a single transmembrane domain protein, termed receptor activity modifying protein, RAMP1, to function as a CGRP receptor. RAMP2 and -3 enable the same CL receptor to behave as an adrenomedullin receptor. Although the calcitonin receptor does not require RAMP to bind and respond to calcitonin, it can associate with the RAMPs, resulting in a series of receptors that typically have high affinity for amylin and varied affinity for CGRP. This review aims to reconcile what is observed when the receptors are reconstituted in vitro with the properties they show in native cells and tissues. Experimental conditions must be rigorously controlled because different degrees of protein expression may markedly modify pharmacology in such a complex situation. Recommendations, which follow International Union of Pharmacology guidelines, are made for the nomenclature of these multimeric receptors.
科研通智能强力驱动
Strongly Powered by AbleSci AI